Google-backed Isomorphic raises $2.1 billion to scale AI-driven drug discovery

Isomorphic Labs, an AI-driven drug discovery firm, has successfully secured $2.1 billion in a Series B funding round, a significant financial boost aimed at accelerating its ambitious mission to cure all diseases. This funding round was led by Thrive Capital, with participation from existing investors including Alphabet and GV (formerly known as Google Ventures). New investors in this round included notable firms such as Abu Dhabi-based MGX, Singapore’s Temasek, Alphabet’s growth stage VC fund CapitalG, and the UK Sovereign AI Fund. The company has not disclosed its valuation following this funding round.

Founded in 2021 as a spinout from DeepMind, Isomorphic Labs is spearheaded by Demis Hassabis, who also serves as CEO of DeepMind, and President Max Jaderberg. The company was established under the auspices of Alphabet to commercialize AI-driven biological breakthroughs, leveraging technologies like AlphaFold. The substantial funding will be allocated towards scaling Isomorphic's drug design engine, known as IsoDDE, and advancing its pipeline of therapeutic candidates with the goal of initiating clinical trials by late 2026.

The fresh capital will also facilitate global hiring across various domains including AI, engineering, drug discovery, and clinical research, which is crucial as the company seeks to enhance its AI models for broader commercial deployment. Isomorphic Labs has already formed strategic partnerships with several major pharmaceutical companies, including Novartis, Eli Lilly and Company, and Johnson & Johnson. These collaborations underscore the commercial viability of Isomorphic's AI-driven approach to drug development.

Demis Hassabis expressed optimism regarding the funding, stating that it represents a significant vote of confidence from a diverse group of top-tier international investors in Isomorphic's AI-first methodology for drug design and development. He emphasized that the company has demonstrated the soundness of its approach and is now focused on scaling its technology to its full potential. The capital infusion will enable Isomorphic to build out its drug design engine at scale, propelling its mission to address various diseases.

Ruth Porat, president and chief investment officer of Alphabet and Google, highlighted the profound opportunities that AI presents in healthcare. She remarked on Isomorphic Labs' extraordinary progress in utilizing AI to accelerate drug discovery and expressed excitement about the momentum and early promise of the technology platform. Porat noted that this funding will expedite the work necessary to bring important medical interventions to market more swiftly.

Isomorphic Labs claims that its proprietary AI models are designed to function across multiple therapeutic areas and drug modalities, which allows for faster and more precise drug discovery. The company has recently published findings that showcase the predictive accuracy and scalability of its AI platform, further solidifying its position in the competitive landscape of AI-driven drug discovery.

The Future of AI in Drug Discovery

The significant investment in Isomorphic Labs signals a growing recognition of the potential that AI holds in revolutionizing drug discovery processes. By harnessing advanced algorithms and machine learning techniques, Isomorphic aims to streamline the traditionally lengthy and costly drug development timeline, which can take years or even decades under conventional methods. The integration of AI into this field not only promises to enhance efficiency but also aims to improve the accuracy of drug candidates, potentially leading to more effective treatments.

The partnerships with established pharmaceutical companies further validate the commercial potential of Isomorphic's technology. These collaborations could facilitate the real-world application of AI-driven insights, bridging the gap between theoretical advancements and practical outcomes in healthcare. As Isomorphic Labs continues to scale its operations, the implications for both creators and technologists in the field are profound, as they may witness a shift in how drugs are discovered and developed.

Why it matters

The implications of Isomorphic Labs' funding extend beyond the company itself, highlighting a broader trend in the intersection of technology and healthcare. For creators, particularly those in the biotech and pharmaceutical sectors, this funding round represents an opportunity to explore innovative applications of AI in their own research and development efforts. The success of Isomorphic Labs could inspire a new wave of startups focused on AI-driven solutions in healthcare, potentially leading to breakthroughs that were previously thought unattainable.

For technologists, the advancements made by Isomorphic Labs serve as a case study in the application of AI to solve complex biological problems. As AI continues to evolve, the demand for skilled professionals in AI, machine learning, and data science will likely increase, shaping the future workforce in these fields. The ongoing developments in AI-driven drug discovery not only promise to enhance patient outcomes but also present a fertile ground for innovation and collaboration among creators and technologists alike.